Department of Orthopaedic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Section for Clinical Biometrics, Centre for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Infection. 2017 Dec;45(6):885-891. doi: 10.1007/s15010-017-1081-5. Epub 2017 Oct 24.
The aim of this study was the evaluation of possible outcome differences of patients undergoing two-stage hip exchange with antibiotic-loaded spacers, compared to patients without an interim spacer implantation.
We evaluated 46 patients undergoing two-stage hip revision surgery. Twenty-five patients received an interim ALS. Additional to a Kaplan-Meier survival analysis, a competing risk analysis was performed to estimate the cumulative incidence function for re-revisions due to infection accounting for death as a competing event.
Nine patients (seven non-ALS vs. two ALS) had to undergo re-revision surgery due to reinfection of the hip joint. The non-ALS group showed a risk of re-revision of 19% (95% CI 5-38%) at 12 and 24 months and 30% (95% CI 12-51%) at 36 months. The group with ALS implantation displayed a 0% risk of re-revision surgery in the first 36 months. The Gray test revealed a significant difference in the cumulative incidence between both observed groups (p = 0.026).
Our findings suggest that ALS implantation significantly reduces the risk of reinfection after two-stage hip revision surgery.
本研究旨在评估接受载抗生素间隔器两期髋关节置换术的患者与未行间隔器植入的患者的可能结局差异。
我们评估了 46 例接受两期髋关节翻修手术的患者。25 例患者接受了 ALS 间隔器。除了 Kaplan-Meier 生存分析外,还进行了竞争风险分析,以估计因感染而导致的髋关节再翻修的累积发生率函数,同时考虑死亡作为竞争事件。
9 例患者(7 例非 ALS 与 2 例 ALS)因髋关节感染复发而需要再次翻修手术。非 ALS 组在 12 个月和 24 个月时髋关节再翻修的风险为 19%(95%CI 5-38%),在 36 个月时为 30%(95%CI 12-51%)。植入 ALS 组在头 36 个月内无髋关节再翻修手术风险。灰色检验显示两组观察到的累积发生率有显著差异(p=0.026)。
我们的研究结果表明,在两期髋关节翻修手术后,ALS 植入显著降低了感染复发的风险。